24 okt: Admiral Capital A/S - Salg af ejendomme
25 okt: Delårsrapport for de første 9 måneder af 2017
24-10-2017 19:42:05

Genmab Announces Additional Information Concerning Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017

Relateret indhold
11:47 - 
Aktier/middag: Trump trækker transportsektor i dybet me..
12 jun - 
Tirsdagens aktier: Pandora og Genmab fik topplaceringer..
12 jun - 
C25-selskaber/Jyske: Dropper dækning af flere selskaber
Relateret debat
17 jun - 
Da mine egne FA-tanker er så få og små..
17 jun - 
Jeg har enkelte gange udtrykt TA holdninger på Pr..
17 jun - 
Så vil jeg - forhåbentlig uden at virke alt..

Company Announcement

  • Johnson & Johnson confirms additional information provided on third quarter 2017 net sales

  • Rest of World third quarter sales reported as USD 87 million

  • The reported number included a one-time adjustment related to accruals of approximately USD 20 million for retroactive reimbursement matters

  • Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.

Copenhagen, Denmark; October 24, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Johnson & Johnson has given additional information relating to rest of world sales of DARZALEX (daratumumab) in the third quarter of 2017. As previously reported, net sales were USD 87 million in the rest of the world. This figure was negatively impacted by a one-time adjustment of approximately USD 20 million related to accruals for retroactive reimbursement matters in Germany and France. Genmab receives royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.

About DARZALEX® (daratumumab)

DARZALEX® (daratumumab) injection for intravenous infusion is indicated in the United States in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (FDA) approval to treat multiple myeloma. DARZALEX is indicated in Europe for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.  In Japan, DARZALEX is approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for treatment of adults with relapsed or refractory multiple myeloma. DARZALEX is the first human CD38 monoclonal antibody to reach the market.  For more information, visit www.DARZALEX.com.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.  Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).1,2,3,4,5

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab.  A comprehensive clinical development program, including multiple Phase III studies, is ongoing with daratumumab in relapsed and frontline multiple myeloma settings, and additional studies are ongoing or planned to assess its potential in other malignant and pre-malignant diseases on which CD38 is expressed, such as smoldering myeloma, NKT-cell lymphoma, amyloidosis, myelodysplastic syndromes and solid tumors.  Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA, for multiple myeloma, as both a monotherapy and in combination with other therapies.  

  

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

  

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.

 

1 DARZALEX Prescribing information, June 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761036s004lbl.pdf  Last accessed June 2017

2 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.

3 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.

4 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.

5 Jansen, JH  et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. Blood. 2012; 120(21):abstract 2974.

Company Announcement no. 35

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 jun
GEN
På proinvestor findes en gruppe personer, der har sat sig rigtig godt ind i casen og følger GEN tæt...
4
17 jun
GEN
Har fulgt dig et stykke tid Balishag, og har faktisk ikke set dig ramme rigtig endnu. Hvad er din tr..
3
16 jun
GEN
Undrer mig lidt over, at Genmab ikke bliver diskuteret så meget på EI. Specielt efter det store fal..
3
17 jun
GEN
Da mine egne FA-tanker er så få og små, så ender det med  kors og bånd med gamle streger på   Test a..
1
17 jun
GEN
Jeg har enkelte gange udtrykt TA holdninger på Proinvestor og må desværre konkludere at negative fre..
1
17 jun
GEN
Ja...et site hvor voksne seriøse?????...investorer i årevis har tiljublet en af de største jokes på ..
1
17 jun
GEN
Proinvestor, der diskuteres akten af voksne mennesker, ingen støj,ingen personfnidder.. ALT er godt...
1
17 jun
GEN
Har haft genmab tidligere. Men har helt droppet alt biotek efter bavarian dykket for noget tid siden..
1

Novo Nordisk indgår forskningssamarbejde inden for fedme og diabetes

19-06-2018 12:16:30
Novo Nordisk har indgået et samarbejde med amerikanske Kallyope om opdagelse af nye lægemidler til behandling af svær overvægt og diabetes.Det fremgår af en pressemeddelelse. Biotekselskabet Kallyope modtager en forudbetaling som led i aftalen og vil modtage forskningsstøtte til aktiviteter under samarbejdet. Hvor stort et beløb, der er tale om, fremgår ikke.Aftalen giver Novo mulighed for at købe..

Nordea: Svensk fagforbund skifter bank efter HQ-flytning til Finland

19-06-2018 11:39:47
Den svenske paraplyfagforening LO skifter transaktionsbank til Swedbank fra Nordea, efter at Nordea sidste år vedtog en flytning af sit hovedkontor fra Stockholm til Helsinki. Den nyhedsbureauet Direkt. - Vi er overbeviste om, at medlemmerne vil have, at vi har vores penge i en svensk bank. Vi er derfor glade for at kunne indlede et samarbejde med Swedbank, som både har base i Sverige og kan lever..

Aktier/tendens: Fokus på Mærsk og DSV i negativ åbning

19-06-2018 08:12:34
Tirsdag er der udsigt til, at det danske aktiemarked fortsætter den faldende tendens fra mandag, efter at USA's præsident, Donald Trump, har truet med at lægge yderligere straftold på en lang række kinesiske varer. Der kan komme fokus på DSV og A.P. Møller-Mærsk.Donald Trump har anmodet landets handelsministerium om at finde kinesiske produkter, der bedst egner sig til nye toldsatser for i alt 200..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Fokus på Mærsk og DSV i negativ åbning
2
Vestas får debutordre i Panama
3
Aktier/middag: Trump trækker transportsektor i dybet med Mærsk forrest
4
Mandagens aktier: Mærsk tyngede C25 - tre selskaber endte i plus
5
Vestas vinder ordre på 228 MW i Australien

Relaterede aktiekurser

Genmab A/S 958,00 0,7% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. juni 2018 16:12:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180619.1 - EUROWEB7 - 2018-06-19 16:12:43 - 2018-06-19 16:12:43 - 1 - Website: OKAY